TRIM24 Overexpression Is Common in Locally Advanced Head and Neck Squamous Cell Carcinoma and Correlates with Aggressive Malignant Phenotypes

Zhibin Cui1,2,9, Wei Cao1,2,9, Jiang Li1,3, Xiaomeng Song1,2, Li Mao1,4*, Wantao Chen1,2*

1 Department of Oral and Maxillofacial Surgery, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2 Shanghai Key Laboratory of Stomatology, Shanghai, China, 3 Department of Oral Pathology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 4 Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, Baltimore, Maryland, United States of America

Abstract

Tripartite motif-containing 24 (TRIM24), a member of the transcriptional intermediary factor 1 family, functions as a coregulator that positively or negatively modulates the transcriptional activities of several nuclear receptors. The aim of this study was to investigate TRIM24 expression and its clinical significance in head and neck squamous cell carcinoma. The expression levels of TRIM24 variants were examined in head and neck squamous cell carcinoma (HNSCC) samples and cell lines by real-time PCR and WB. The expression levels of TRIM24 measured in 91 locally advanced HNSCC tumors were measured by immunohistochemistry and correlated with clinical and pathological parameters. The functional role of TRIM24 in HNSCC was further investigated by silencing its expression in HNSCC cell lines. TRIM24 variants were up-regulated in 56 HNSCC samples (P<.001) and 9 HNSCC cell lines (P<.05). TRIM24 protein was overexpressed in 6 of 8 HNSCC cell lines and in 2 of 3 HNSCC samples. Furthermore, 54.95% (50/91) of HNSCC samples exhibited remarkably elevated expression of TRIM24 by immunohistochemistry. Univariate analysis revealed that high TRIM24 expression was associated with worse overall survival (P=.020). In multivariate analysis, TRIM24 expression was identified as an independent predictor of overall survival (P=.030), after adjusting for other clinicopathological parameters. Upon TRIM24 silencing, the proliferation of HNSCC cells was notably inhibited due to the induction of apoptosis. These results suggest that aberrant TRIM24 expression may play an important role in the development of HNSCC and is a promising prognostic indicator for patients with locally advanced HNSCC.

Citation: Cui Z, Cao W, Li J, Song X, Mao L, et al. (2013) TRIM24 Overexpression Is Common in Locally Advanced Head and Neck Squamous Cell Carcinoma and Correlates with Aggressive Malignant Phenotypes. PLoS ONE 8(5): e63887. doi:10.1371/journal.pone.0063887

Editor: Gnanasekar Munirathinam, University of Illinois, United States of America

Received December 13, 2012; Accepted April 8, 2013; Published May 22, 2013

Copyright: © 2013 Cui et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by the National Natural Science Foundation of China (81072171, 30973343 and 91229103), Projects of the Shanghai Science and Technology Committee (08JC1414400, 10DZ1951300, 11DZ2291800 and 10XD1402500). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: lmao@umaryland.edu (LM); chenwantao2002@hotmail.com (WC)
† These authors contributed equally to this work.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is one of the 10 most common malignancies in the world with more than 500,000 new cases are reported annually. It is widely recognized as a heterogeneous tumor type with various aggressive malignant phenotypes [1]. For those with locally advanced tumors, the 5-year survival rate is approximately 40%. It is well established that the heterogeneous tumor type with various aggressive malignant phenotypes play critical roles [2,3,4,5]. Better understanding the molecular basis of HNSCC should further facilitate development of novel strategies to improve early diagnosis and treatment of the disease.

Tripartite Motif-Containing 24 (TRIM24) belongs to a subgroup of the large family of tripartite-motif (TRIM) proteins. All TRIM proteins contain several conserved domains: a RING finger, one or two zinc-binding motifs named B-boxes and a coiled-coil region [6]. It was reported that the three conserved motifs work together to degrade wild-type p53 protein by tagging it with ubiquitin [7,8]. The inactivation of TRIM24 together with TRIM28 or TRIM33 in mice disturbs RA-signaling in hepatocytes, resulting in the development of hepatocellular carcinoma in a cell-autonomous manner [9,10]. Additionally, in vitro studies have suggested that TRIM24 negatively regulates prostate cancer cell proliferation through binding to bromodomain containing 7, which represses androgen receptor transactivation activity [11]. Meanwhile, TRIM24 can bind chromatin and the estrogen receptor to activate estrogen-dependent genes associated with cell proliferation and tumor development in breast [12]. Furthermore, the aberrant expression of TRIM24 is significantly associated with poor prognosis patients with breast cancer [13].

In this study, we evaluated the expression profile of TRIM24 in patients with HNSCC and found that TRIM24 is frequently overexpressed. The up-regulation of TRIM24 was significantly associated with worse overall survival in patients with locally advanced HNSCC. Furthermore, our data indicate that TRIM24 plays a critical role in promoting growth and survival of HNSCC.
cells in vitro. To the best of our knowledge, our results provide the first evidence suggesting TRIM24 as an independent prognostic indicator for patients with locally advanced HNSCC.

Materials and Methods

Patients and Specimens

TRIM24 mRNAs were evaluated by real-time PCR in 56 pairs of HNSCC samples and adjacent normal tissues. The samples were obtained from patients with locally advanced HNSCC who were diagnosed at the Ninth People’s Hospital of the Shanghai Jiao Tong University School of Medicine from 1999 to 2004. The medical records of the patients were reviewed for inclusion and exclusion criteria. Exclusion criteria included patients with recurrent tumors; preoperative radiotherapy and/or chemotherapy; clinical stage I/II diseases; distant metastasis; and incomplete medical records. This cohort included 67 men (73.6%) and 24 women (26.4%) with a median follow-up of 102 months (interquartile range, 78–110 months). Detailed clinicopathological parameters are summarized in Table 1. The tumors from each patient were stained with hematoxylin and eosin (H&E), classified histologically, and staged according to the International Union Against Cancer TNM classification system (5th Edition). Each sample has more than 50% of malignant tissue.

Real-Time PCR Analysis

Two TRIM24 isoforms [13] were analyzed using two pairs of primers to detect variants 1 and 2. A primer set, which amplifies both isoforms (referred as “core”), was used as a control. The expression levels of TRIM24 variants were examined in 9 HNSCC cell lines, 1 immortalized keratinocyte cell line and 1 primary normal keratinocyte culture, as well as in 56 HNSCC samples and the paired adjacent normal tissues by real-time PCR. All real-time PCR reactions were performed as previously described [14]. The primers used for TRIM24 variants were as follows: 5′-AATGGACCACTTTCTCTCTCTCA-3′ and 5′-TGTCGTTTTATGTTGCGTG-3′ for total TRIM24; 5′-GGTATCACGCAACCTGAAGTGCAGG-3′ and 5′-AAGTTTATGGAACGTGGAGGCC-3′ for TRIM24 variant 1; 5′-CAGGAACAGACACCCTC-3′ and 5′-TGAGGAGGGAAGACTGTTCCAT-3′ for TRIM24 variant 2; 5′-CCTGGCCACCAGCAAT-3′ and 5′-GGCCGGGACTGTCATACT-3′ for β-actin. Primers for the nuclear factors are as follows: 5′-AAAGCCCGAGTCTGCTCTGAGA-3′ and 5′-TTGTCGTTATGTTGAGCCGC-3′ for RARA; 5′-TCCGAAAAGCTCACCAGGA-3′ and 5′-GGCCGTTCTGAAATTTGCTCC-3′ for RARB; 5′-GGCTACCAAGTGCTATCACC-3′ and 5′-TGTCGAGA-TACGCGATCATCAG-3′ for RARC; 5′-AGTCATCGGTCA-GACACCTTT-3′ and 5′-TGTCGAGCGTTATCCTACGAC-3′ for AR. The ΔΔCt method was applied to calculate the TRIM24 expression levels in tumor tissues relative to the normal adjacent tissues. Here, ΔΔCt is the difference in the Ct values derived from the specific genes compared with β-actin. Primers for the nuclear factors are as follows: 5′-AAAGCCCGAGTCTGCTCTGAGA-3′ and 5′-TTGTCGTTATGTTGAGCCGC-3′ for RARA; 5′-TCCGAAAAGCTCACCAGGA-3′ and 5′-GGCCGTTCTGAAATTTGCTCC-3′ for RARB; 5′-GGCTACCAAGTGCTATCACC-3′ and 5′-TGTCGAGA-TACGCGATCATCAG-3′ for RARC; 5′-AGTCATCGGTCA-GACACCTTT-3′ and 5′-TGTCGAGCGTTATCCTACGAC-3′ for AR. The ΔΔCt method was applied to calculate the TRIM24 expression levels in tumor tissues relative to the normal adjacent tissues. Here, ΔΔCt is the difference in the Ct values derived from the specific genes compared with β-actin. ΔΔCt T (Tumor) = Ct value (TRIM24 in tumor tissue) - Ct value (β-actin in tumor tissue); whereas ΔΔCt N (Normal) = Ct value (TRIM24 in normal tissue) - Ct value (β-actin in normal tissue). The relative expression levels of TRIM24 mRNA normalized to β-actin were represented as –ΔΔCt value here. Thus, higher ΔΔCt values correspond to lower relative expression levels of TRIM24 mRNA. The significance level was set at P<.01.

Western Blot Analysis

Cells and tissue samples were lysed in radioimmunoprecipitation assay buffer (Sigma-Aldrich, St. Louis, MO). The lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Primary antibodies against TRIM24 (ProteinTech, Chicago, IL) were used to evaluate protein levels, and GAPDH or β-actin antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA) was used to normalize the protein loading. Bands were detected using an IRDye 800-conjugated affinity-purified antimouse immunoglobulin M antibody (Rockland, Gilbertsville, PA). The membrane was then washed several times and scanned using the Odyssey infrared imaging system (LICOR, Lincoln, NE) in the
800-channel wavelength and analyzed with Odyssey software. Finally, bands were quantified using the Image J processing and analysis software.

Immunohistochemical Staining

The avidin-biotin complex (ABC) staining technique was performed according to the manufacturer’s instructions for the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA), as described previously [15]. Briefly, tissue sections were deparaffinized in xylene, rehydrated in graded ethanol, treated with Tris-ethylene diamine tetraacetic acid buffer or citrate buffer for antigen retrieval, and quenched in hydrogen peroxide. The tissue sections were then blocked with 2.5% normal serum, incubated overnight at 4°C with anti-TRIM24 antibody (1:500 dilution; Proteintech, Chicago, IL) followed by incubating with biotinylated secondary antibody and ABC reagent. Diaminobenzidine was used as chromogen, and sections were counterstained with Mayer hematoxylin (Sigma-Aldrich, St. Louis, MO). The labeling index was defined semi-quantitatively as the intensity of staining (0, 1, 2, or 3) multiplied by the percentage of positive tumor cells (25, 50, or 75). A pathologist randomly examined 7 to 10 tumor areas in each section, and the final scores ranging from 0 to 300 were calculated. For TRIM24 staining, we divided the cases into 4 grades by scores. The cases scored from 0 to 25 were marked as negative (-); cases scored from 25 to 100 were marked as low grade (+); cases scored from 100 to 225 were marked as median grade (++); and cases scored from 225 to 300 were marked as high grade (+++). We also defined the negative (-) and low (+) grades cases as low TRIM24 expression whereas the median (+++) and high (++++) grades cases as high TRIM24 expression.

Cell Culture

The HNSCC cell lines WSU-HN4, HN6, HN12, HN13, and HN30 (kindly provided by the University of Maryland School of Dentistry) were cultured in Dulbecco’s modified Eagle medium (DMEM) (GIBCO-BRL, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (GIBCO-BRL), penicillin (100 unit/mL), and streptomycin (100 μg/mL) at 37°C in a humidified 5% CO2 atmosphere. CAL27, SCC4, SCC9, and SCC25 cells (purchased from the American Type Culture Collection, Manassas, VA) were cultured in DMEM/F12 medium (GIBCO-BRL) supplemented with 10% heat-inactivated FBS, penicillin (100 unit/mL), and streptomycin (100 μg/mL). Immortalized oral epithelial cells infected with human papillomavirus type 16-E6/E7 (HPV16E6/E7) were cultured in a defined keratinocyte serum-free medium (GIBCO-BRL) [16]. Normal human oral mucosa were harvested from the area adjacent to the area of tooth extraction at Oral and Maxillofacial Surgery outpatient clinic. The tissue was incubated with dispase overnight to separate the surface epithelium from the underlying fibrous connective tissue. The epithelium was then trypsinized to prepare a single cell suspension. Primary normal human oral mucosa cells were cultured in the keratinocyte serum-free medium (GIBCO-BRL) as described in the previous study [17].
Figure 2. TRIM24 protein expression in HNSCC cell lines and primary HNSCC tissues. (A) TRIM24 protein detected in 8 HNSCC cell lines. (B) Protein levels of TRIM24 in 3 paired HNSCC tissues and the paired adjacent normal tissues. (C) and (D) protein expression levels of TRIM24 quantified using Image J processing and analysis software. doi:10.1371/journal.pone.0063887.g002

Figure 3. Immunohistochemical staining of TRIM24 expression in 91 tumors from HNSCC patients. (A-D) Different patterns of TRIM24 expression in HNSCC tissues (200X). (A) Example of scores 0-25 (-); (B) Scores 25-100 (+); (C) Scores 100-225 (++); and (D) Scores 225-300 (+++). (E-H) Different patterns of TRIM24 expression in HNSCC tissue (400X). doi:10.1371/journal.pone.0063887.g003
Small Interfering RNA Transfection
Small interfering RNAs (siRNAs) targeting the two splice variants of TRIM24 and FAM-labeled negative control siRNA were purchased from Shanghai GenePharma Company, Ltd. (Shanghai, China). The siRNA sequences used were 5'-AAG-CAGGTGGAACAGGATATTAAAGTTGC-3' (siRNA for TRIM24) and 5'-ACGUGACACGUUCGGAGAATT-3' (negative control siRNA). Sequences of TRIM24-siRNA1 and TRIM24-siRNA2 in Figure S1 were 5'-AAAGCCAGGCTCATTTCATGG-3' and 5'-AAAGTAATGCTGTACTGCTGC-3'. In vitro transient transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as described previously [18].

Cell Proliferation Assay
Cell-proliferation assay was performed to analyze the proliferation potential of WSU-HN6 and SCC25 cells that were transiently transfected TRIM24 siRNA or negative control siRNA. The cells were harvested and plated in 96-well plates at 1×10^3 cells per well and maintained at 37°C in a humidified incubator. At the indicated time points, 10 μL of CCK-8 solution was added to the wells and incubated for 1 hour, and the absorbance at 450 nm was measured to calculate the number of viable cells in each well. Measurements were performed in triplicate, and the mean (standard deviation) optical density was reported.

Colony Formation Assay
Briefly, TRIM24-siRNA-transfected and control-siRNA-transfected WSU-HN6 cells (1×10^3 cells per plate) and SCC25 (2×10^3 cells per plate) cells were seeded in a 10 mm plate and cultured in complete medium for 1 week. Cell colonies were then visualized by 0.25% crystal violet. After washing out the dye, colonies containing >50 cells were counted.

Cell Apoptosis Assay
Apoptosis was assessed using Annexin V-PI staining 48 hours after transfection. Then, these cells were quantified by flow cytometry using the Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer’s protocols. Briefly, floating cells and trypsinized adherent cells were pooled and suspended in 100 μL of Annexin V-FITC Binding Buffer. Then, 5 μL of Annexin V-FITC and 5 μL of PI were added, and the cells were incubated for 15 minutes at 25°C. The cells were then resuspended in 400 μL of the Annexin V-FITC binding buffer and analyzed immediately by flow cytometry. Then, 10,000 events were scored by FACS Calibur and analyzed using Cell Quest software.

Figure 4. Analysis of TRIM24 expression with its clinical prognosis. (A and B) Results of TRIM24 expression status were showed in the 91 HNSCC tissues; (C and D) Kaplan-Meier survival curves for overall survivals based on TRIM24 staining patterns.

doi:10.1371/journal.pone.0063887.g004
Overexpression of TRIM24 in HNSCC

Both core and two variants of TRIM24 mRNA were expressed higher in the 9 HNSCC cell lines and the immortalized cell line than in the primary normal keratinocytes (Fig. 1A–C). Similarly, TRIM24 mRNA levels were higher in HNSCC tissues compared to adjacent normal tissues in the 56 HNSCC patients (Fig. 1D–F). On Western blots, TRIM24 protein is highly expressed in all HNSCC cell lines comparing to the normal oral mucosa cells. While in the HNSCC cell lines, HN30 and HN13 and SCC4 was expressed lower than the other HNSCC cell lines (Figure 2 A). In paired HNSCC tissues and their adjacent normal tissues, 2 of the 3 showed higher TRIM24 levels in the tumors than in the adjacent normal tissues (Fig. 2).

TRIM24 Protein Overexpression Correlates with Poor Prognosis in HNSCC Patients

We investigated TRIM24 protein expression pattern using immunohistochemical staining in 91 tumor samples from patients with locally advanced HNSCC and analyzed the correlations between TRIM24 expression and clinical outcome using Kaplan-Meier survival analysis. TRIM24 staining was mainly located in the nuclei of the tumor cells, as shown in Figure 3. TRIM24 was expressed at high level in 15.1% (50/319) the tumors (Fig. 4A). Notably, patients whose primary tumors exhibited high levels of TRIM24 (mean labeling index of 150 was used as a cutoff value) had significantly poorer overall survival (P = 0.02) (Fig. 4C).

To further analyze the correlation, we classified the expression level of TRIM24 into four subgroups and performed further correlation analyses. Twenty-nine patients (24.2%) were negative for TRIM24 (-), nineteen (20.9%) patients were classified as having low TRIM24 expression (+), thirty-six (39.6%) were classified as median (++), and fourteen (15.3%) were classified as high (+++) (Fig. 4B). A expression level dependent relationship with the overall survivals was observed (P = 0.024) (Fig. 4D).

Univariate and Multivariate Survival Analysis

Univariate and multivariate survival analyses were performed to further evaluate whether TRIM24 expression is an independent prognostic indicator in locally advanced HNSCC patients. In the univariate Cox proportional analysis, TRIM24 expression (hazard ratio, 1.910; 95% CI, 1.088-3.352; P = 0.024), tumor grade (hazard ratio, 1.825; 95% CI, 1.060-3.143; P = 0.030), lymph node metastasis (hazard ratio, 2.269; 95% CI, 1.390-3.703; P = 0.001) and histological signs of severity (including vascular embolization, perineural invasion, and diffuse invasion. Hazard ratio, 2.636; 95% CI, 1.338-4.520; P < 0.001) were significantly correlated with the overall survival of the patient population (Table 2). In the multivariate analysis, after adjusting for tumor grade and lymph node metastasis, only TRIM24 expression (hazard ratio, 1.910; 95% CI, 1.064-3.428; P = 0.030) and lymph node metastasis (hazard ratio, 2.837; 95% CI, 1.492-5.396; P = 0.015) were identified as independent factors contributing to the worse overall survival (Table 3).
inhibited colony formation of WSU-HN6 (P < .01) and SCC25 (P < .01) cells (Fig. 5E). To determine whether the growth inhibition was due to the induction of apoptosis, we measured the apoptosis of the cells using Annexin V-FITC/PI double staining. The number of early apoptotic cells was significantly increased in WHU-HN6 cells transfected with TRIM24 siRNA at 48 hours compared with control siRNA-transfected cells (P = .05) (Fig. 6 A and B).

TRIM24 Silencing Induces the Expression of Nuclear Receptors
Previous studies showed that TRIM24 regulates transcriptional activities of various nuclear receptors including RAR and AR. We then performed real-time PCR to test the expression profiles of RAR and AR in WSU-HN6 cell line treated with siRNA transfection. Finally we found that the down regulation of TRIM24 induces high expression of RARB (P < .0001) and RARC (P = .003), while there is no such correlation between TRIM24 and RARA (P = .17) and AR (P = .49) (Figure 6 C).

Discussion
In this study, we found that TRIM24, also called TIF-1, was frequently up-regulated at both mRNA and protein levels in HNSCC, in cell lines and primary tumors. As previous studies showed that TRIM24 expression is up-regulated in breast cancer,
myelodysplastic syndrome-related acute myeloid leukemia and sporadic colorectal cancers [13,19,20], our results support that aberrant expression of TRIM24 is common in multiple tumor types and may contribute to initiation and/or progression of these tumors. Using array CGH analysis, gains at the TRIM24 locus (7p34) were detected in approximately 10% of the breast cancers suggesting that genomic alterations may partly account for the TRIM24 overexpression in breast cancer [13]. Whether the genetic or the epigenetic factors contribute to the increased expression of TRIM24 in HNSCC remains to be determined in future studies. Earlier studies suggest that the increased levels of TRIM24 mRNA might not directly link to the increased protein levels due to other factors such as post-transcriptional regulation, epigenetic modifications or microRNA regulation [21,22]. In this

Figure 6. Apoptosis analysis of WSU-HN6 with TRIM24 down-regulation. (A) Annexin V-FITC-propidium iodide flow cytometry of WSU-HN6 cells with and without TRIM24 down-regulation; (B) Shows their quantified image; (C) mRNA expression of nuclear receptors in WSU-HN6 cells with TRIM24-siRNA and its control-siRNA.
doi:10.1371/journal.pone.0063887.g006
study, we measured both mRNA and protein levels of TRIM24 and found that TRIM24 expression was increased in the HNSCC cell lines and primary tumor tissues at both mRNA and protein levels. An important goal of studying molecular abnormalities in cancers is to translate the knowledge into clinical applications [23]. To develop clinically useful biomarkers, we need to take steps to validate these markers. In this study, we applied immunohistochemical staining to determine TRIM24 expression status in an independent cohort of patients with HNSCC to validate findings obtained from our first set of patients. High expression of TRIM24 in the locally advanced HNSCC indicates it is common event in the tumor type. TRIM24 staining was found predominantly in nuclei, suggesting it may function as a transcriptional regulator in cancer cells as suggested in a previous study [13]. The finding that the aberrant expression of TRIM24 correlates with the poor survival of patients with HNSCC is significant because it suggests TRIM24 may play an important biological role in the progression of HNSCC and be used as a biomarker to predict clinical outcome of patients with HNSCC. Together with other biomarkers, TRIM24 status may help the implementation of optimized therapeutic strategies for HNSCC [24,25].

A recent functional study, Allton et al. showed that TRIM24 (also called bonus in Drosophila) can negatively regulate p53 and that loss of TRIM24 can cause p53-dependent apoptosis in human breast cancer cells [7]. TRIM24 regulates the p53 degradation as an E3-ubiquitin ligase, while there are quantity of negative regulators (including other ubiquitin E3-ligases, i.e. MDM2) that could play the role in degrading the p53. During our study, we down-regulated the expression of TRIM24 alone and did not find the up-regulation of p53. Chambon et al., analyzed the tissue microarray of breast cancer samples and did not find correlations between TRIM24 expression and p53 status. The author discussed p53 E3-ubiquitin ligase activity by TRIM24 may be clearly tested in the liver-specific environment where p53 response to environmental stress like ultraviolet irradiation [13]. Meanwhile, Allton et al. validated the TRIM24 could bind to the p53 thus leads to p53 degradation, while depletion of TRIM24 did not lead to an up-regulation of p53 (p>0.05) in their supplementary data. According to the combination of the reported and our tests, we deemed that in HNSCC TRIM24 may degrade the p53 protein as an E3-ubiquitin ligase but may not be a drive factor responsible for p53 degradation and not directly influence the p53 protein stability. TRIM24 related p53 issue need far more research not only in HNSCC but also in most solid tumors.

Other studies showed that TRIM24 is overexpressed in acute promyelocytic leukemia and papillary thyroid carcinomas, respectively, and is a chromosomal translocation target of Braf (T18) and Ret oncogenes [18,26,27]. These results support the role of TRIM24 as an oncogene. However, using transgenic animals, studies showed that TRIM24 may play a role in suppressing liver tumorigenesis [9,10]. Such effect is possible because TRIM24 contains a nuclear receptor interaction domain (NRID) which can interact with many nuclear receptors such as retinoic acid receptor-alpha (RARα), retinoic acid receptor-X (RXR), vitamin D3 (VDR), estrogen (ER) and progesterone (PR) receptors [28]. These interactions make TRIM24 a co-regulator of various functions via trans-activation processes [29]. Thus, the roles of TRIM24 are complex and different in tumorigenesis of various organ systems. Nevertheless, our data support an oncogenic role of TRIM24 in HNSCC because not only the correlation between higher expression of TRIM24 and poorer clinical outcomes but also TRIM24 can promote growth and preventing apoptosis in HNSCC cells. Further studies will be needed to determine the mechanisms of TRIM24 in promoting head and neck tumorigenesis.

Supporting Information
Figure S1 Two TRIM24-siRNAs were used to eliminate the side effect in WSU-HN6 cells. (A) Knockdown effects of TRIM24-siRNAs in WSU-HN6 cells. (B) Growth curve of WSU-HN6 with TRIM24-siRNAs and control-siRNA. (TIF)

Author Contributions
Conceived and designed the experiments: ZBC WTC LM. Performed the experiments: ZBC WTC LM. Analyzed the data: JL. XMS. Contributed reagents/materials/analysis tools: XMS JL. Wrote the paper: ZBC WTC LM. Obtained permission for use of cell lines: LM.

References
1. Arginis A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371: 1695–709.
2. Cabanillas R, Rodrigo JP, Astudillo A, Dominguez F, Suarez C, et al. (2007) P53 expression in squamous cell carcinomas of the supraglottic larynx and its lymph node metastases: new results for an old question. Cancer 109: 1791–1796.
3. Chung CH, Ely K, McGavran I, Varella-Garcia M, Parker J, et al. (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170–4176.
4. Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, et al. (2006) Molecular and cytogenetic subgroups of erythroleukemia squamous cell carcinoma. Clin Cancer Res 12: 6653–6651.
5. Martone T, Gillio-Tos A, De Marco L, Fiano V, Maule M, et al. (2006) Association between hypermethylated tumor and paired surgical margins in head and neck squamous cell carcinomas. Clin Cancer Res 13: 5089–5094.
6. Hatakeyama S (2011) TRIM proteins and cancer. Nat Rev Cancer 11: 792–804.
7. Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, et al. (2009) TRIM24 targets endogenous p53 for degradation. Proc Natl Acad Sci USA 106: 11612–11616.
8. Jain AK, Barton MC (2009) Regulation of p53: TRIM24 enters the RING Cycle 8: 3668–3674.
9. Khetoumian K, Teflet M, Tisserand J, Mark M, Herquel B, et al. (2007) Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet 39: 1500–1506.
10. Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, et al. (2011) Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress marine hepatocellular carcinoma. Proc Natl Acad Sci USA 108: 8212–8217.
11. Kikuchi M, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, et al. (2011) TRIM24 mediates ligand-dependent activation of androgen receptor and is expressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim Biophys Acta 1795: 1029–1036.
12. Tsai WW, Wang Z, Yin TT, Akdemir KC, Xia W, et al. (2010) TRIM24 links a non-canonical histone signature to breast cancer. Nature 468: 927–932.
13. Chambon M, Orsetti B, Berthe ML, Bascoul-Mollevi C, Rodriguez C, et al. (2011) Prognostic significance of TRIM24/TIF1alpha gene expression in breast cancer. Am J Pathol 178: 1461–1469.
14. Cao W, Zhang ZY, Xu Q, Sun Q, Yan M, et al. (2010) Epigenetic silencing of MAL1, a putative tumor suppressor gene, can contribute to human epithelium cell carcinoma. Mol Cancer 9: 296.
15. Cao W, Feng Z, Cui Z, Zhang C, Sun Z, et al. (2012) Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer 118: 2083–2091.
16. Zhang LP, Pan HY, Zhou NJ, Ye DX, Zhang L, et al. (2008) Characteristics of a cancerous cell line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human immortalized oral epithelial cell line. Arch Oral Biol 53: 443–452.
17. Oda D, Watson E (1990) Human oral epithelial cell culture. I. Improved conditions for reproducible culture in serum-free medium. In vitro Cell Dev Biol 26: 589–595.
18. Cao W, Younis RH, Li J, Chen H, Xia R, et al. (2011) EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prev Res (Phila) 4: 1816–1824.
19. Gandini D, De Angeli C, Aguiari G, Manzati E, Lanza F, et al. (2002) Characteristics of a immortalized oral epithelial cell line. Arch Oral Biol 53: 443–452.
20. Zhong LP, Pan HY, Zhou NJ, Ye DX, Zhang L, et al. (2008) Characteristics of a cancerous cell line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human immortalized oral epithelial cell line. Arch Oral Biol 53: 443–452.
20. Popanda O, Zheng C, Mapleburg JR, Büttner J, Flohr T, et al. (2000) Mutation analysis of replicative genes encoding the large subunits of DNA polymerase alpha and replication factors A and C in human sporadic colorectal cancers. Int J Cancer 86: 318–324.
21. Matsuhara N (2012) Epigenetic regulation and colorectal cancer. Matsuhara N. Dis Colon Rectum 55: 96–104.
22. Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E (2011) MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 117: 1630–1639.
23. Ammerpoht O, Siebert R (2011) How to analyse epigenetic marks? Pediatr Endocrinol Rev; 9 Suppl 1: 511–514.
24. Pulte D, Brenner H (2010) Changes in survival in head and neck cancers in the late 20th and early 21st century: A period analysis. Oncologist 15: 994–1001.
25. Marur S, Forastiere AA (2008) Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83: 489–501.
26. Klugbauer S, Rabes HM (1999) The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene 18: 4381–4393.
27. Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, et al. (1995) The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J 14: 2020–2033.
28. Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeannougin F, et al. (1996) A possible involvement of TIF1alpha and TIF1beta in the epigenetic control of transcription by nuclear receptors. EMBO J 15: 6701–6715.
29. Peng H, Feldman I, Rauscher FJ 3rd (2002) Hetero-oligomerization among the TIF family of RBBP/TRIM domain-containing nuclear cofactors: a potential mechanism for regulating the switch between coactivation and corepression. J Mol Biol 320: 629–644.